erlotinib hydrochloride has been researched along with niclosamide in 3 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (niclosamide) | Trials (niclosamide) | Recent Studies (post-2010) (niclosamide) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 979 | 19 | 465 |
Protein | Taxonomy | erlotinib hydrochloride (IC50) | niclosamide (IC50) |
---|---|---|---|
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 13.7 | |
Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 10 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.28 | |
Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 10 | |
Signal transducer and activator of transcription 3 | Homo sapiens (human) | 0.23 | |
Anoctamin-1 | Homo sapiens (human) | 0.028 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Chen, ZG; Curran, WJ; Deng, X; Hu, Z; Khuri, FR; Li, R; Owonikoko, TK; Ramalingam, SS; Sica, GL; Sun, SY | 1 |
Chen, ZG; Curran, WJ; Deng, X; Hu, Z; Khuri, FR; Li, R; Shin, DM; Sica, GL; You, S | 1 |
Chella, N; Kumar, P; Padakanti, AP; Pawar, SD | 1 |
3 other study(ies) available for erlotinib hydrochloride and niclosamide
Article | Year |
---|---|
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Topics: Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mutation; Niclosamide; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Niclosamide; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor | 2013 |
Development and validation of HPLC method for simultaneous estimation of erlotinib and niclosamide from liposomes optimized by screening design.
Topics: Chromatography, High Pressure Liquid; Drug Liberation; Erlotinib Hydrochloride; Liposomes; Niclosamide; Particle Size | 2023 |